Jasper Therapeutics (NASDAQ:JSPR) Issues Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) announced its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.47, reports.

Jasper Therapeutics Trading Down 14.3%

NASDAQ JSPR opened at $0.90 on Tuesday. The stock has a market capitalization of $25.18 million, a price-to-earnings ratio of -0.15 and a beta of 3.08. The business’s 50 day moving average is $1.33 and its two-hundred day moving average is $1.77. Jasper Therapeutics has a 12-month low of $0.88 and a 12-month high of $7.19.

Institutional Trading of Jasper Therapeutics

Institutional investors have recently modified their holdings of the business. Quadrature Capital Ltd acquired a new position in Jasper Therapeutics during the fourth quarter worth $123,000. Millennium Management LLC lifted its holdings in Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after acquiring an additional 708,844 shares during the period. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics during the 4th quarter worth $26,000. Boothbay Fund Management LLC boosted its position in shares of Jasper Therapeutics by 79.4% during the 4th quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock worth $1,453,000 after purchasing an additional 351,312 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $256,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Rodman & Renshaw initiated coverage on Jasper Therapeutics in a research note on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Finally, UBS Group started coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.88.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.